Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3D: Allogeneic AdMSC in Mild to Moderate Alzheimer Disease
NCT07367815Phase 2Recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial in Alzheimer's disease (AD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Number of participants with a clinically significant serious or non-serious AE related to treatment at 6 months. Started May 2026; status: recruiting.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07367815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367815.